Luyten, A
Dana P GoldmanDana P Goldman is an Influencer Founding Director, USC Schaeffer Institute | University Professor of Public Policy, Pharmacy, and Economics | LinkedIn Top Voice Good news for reducing the burden of cardiovascular disease
Inertia Procrastination, driven by the reluctance to embrace change, is what hinders ones progress
It functions as a permeation enhancer, allowing drugs with naturally low bioavailability to pass more effectively through the gastrointestinal tract
The Phase 2 SYNERGY-NASH trial was a 52-week, dose-finding study that evaluated Tirzepatide in 190 participants with biopsy-confirmed MASH and moderate-to-severe (stage F2 or F3) liver fibrosis
The oral segment is expected to expand at the fastest CAGR in the upcoming period, owing to increasing patient preference for non-injectable options and advancements in drug formulation technology